Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | HRH2 | P25021 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25188272 | 0.91 | SIGMAR1 (0.42) | SIGMAR1DRD2DRD4FAAHNR1H2 | |
| SCHEMBL25197462 | 0.90 | SIGMAR1 (0.42) | SIGMAR1DRD2DRD4FAAHNR1H2 | |
| SCHEMBL25190061 | 0.85 | NR1H2 (0.52) | SIGMAR1DRD2DRD4FAAHNR1H2 | |
| SCHEMBL25188441 | 0.84 | KDM4E (0.43) | SIGMAR1DRD2DRD4FAAHHRH2 | |
| SCHEMBL25188873 | 0.82 | POLB (0.43) | SIGMAR1DRD2DRD4FAAHNR1H2 | |
| SCHEMBL25189357 | 0.81 | SMN1; SMN2 (0.48) | SIGMAR1DRD2DRD4 | |
| SCHEMBL25201553 | 0.79 | SIGMAR1 (0.41) | SIGMAR1DRD2DRD4FAAHHRH2 | |
| SCHEMBL31253697 | 0.76 | SIGMAR1 (0.41) | SIGMAR1DRD2DRD4FAAH | |
| SCHEMBL19549747 | 0.71 | SLC18A3 (0.50) | SIGMAR1DRD2ALDH1A1 | |
| SCHEMBL19549750 | 0.71 | SLC18A3 (0.50) | SIGMAR1DRD2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270210-A1 | BCL-2 Inhibitor | BEIGENE, LTD. (KY) | 2025-08-28 | — | — | US | disclosed |
| US-12286430-B2 | Bcl-2 inhibitor | BEIGENE, LTD. (KY) | 2025-04-29 | — | — | US | disclosed |
| US-20240376097-A1 | BCL-2 Inhibitor | BEIGENE LTD. (KY) | 2024-11-14 | — | — | US | disclosed |
| CN-116969936-A | BCL-2 inhibitors | 百济神州有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116969937-A | BCL-2 inhibitors | 百济神州有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116802179-A | BCL-2 inhibitors | 百济神州有限公司 | 2023-09-22 | — | — | CN | disclosed |
| US-20230159522-A1 | BCL-2 INHIBITOR | BEONE MEDICINES I GMBH (CH) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270210-A1 | BCL-2 Inhibitor | BCL2, BCL2A1, BCL2L1 | SIGMAR1 4650/4885DRD2 3220/4885DRD4 4343/4885 |
| US-20230159522-A1 | BCL-2 INHIBITOR | BCL2, BCL2A1, BCL2L1 | SIGMAR1 4650/4885DRD2 3220/4885DRD4 4343/4885 |
| US-20240376097-A1 | BCL-2 Inhibitor | BCL2, BCL2A1, BCL2L1 | SIGMAR1 4650/4885DRD2 3220/4885DRD4 4343/4885 |
| US-12286430-B2 | Bcl-2 inhibitor | BCL2, BCL2A1, BCL2L1 | SIGMAR1 4650/4885DRD2 3220/4885DRD4 4343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.